GL1X · GenesisL1 explorer

Research workbench

Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric inhibitor SHP504

Analyse Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6BMV
Type
protein
Length
964 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein phosphatase non-receptor type 11
EC
3.1.3.48
UniProt
Q06124
Ligands
DZS, PO4
Pockets
12 · best druggability 0.70

Structure

x-ray diffraction · 2 distinct chains · 30% helix, 26% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein48330% helix, 26% strandQ06124
BTyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein48131% helix, 26% strandQ06124

Ligands and binding sites

  • DZS · 3-{4-[(2-chlorophenyl)methyl]-5-oxo-4,5-dihydro[1,2, 4]triazolo[4,3-a]quinazolin-1-yl}-4-hydroxybenzoic acid · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19420.700.7580empty
24060.620.7734empty
33630.620.7832empty
41390.550.8226empty
5930.510.8323PO4

Interfaces

1 interface between chains.

  • A–B · 161 Ų buried · 2 hydrogen bonds · protein-protein

Compared structures

  • 6BMV · Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP504 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.